SIR RORY COLLINS
FRCP, FMedSci, Chief Executive, UK Biobank (Oxford)
Rory Collins was appointed Principal Investigator and Chief Executive of UK Biobank in September 2005. Rory qualified in medicine at St Thomas's Hospital Medical School, University of London, in 1981 and obtained BSc in statistics from George Washington University, Washington DC in 1977 and MSc in statistics from the University of Oxford in 1983. In 1985, he became co-director, with Professor Sir Richard Peto, of the University of Oxford's Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU). In 1996 he was appointed Professor of Medicine and Epidemiology at Oxford, supported by the British Heart Foundation. His work has been in the establishment of large-scale epidemiological studies of the causes, prevention and treatment of heart attacks, other vascular disease, and cancer, while also being closely involved in developing approaches to the combination of results from related studies (“meta-analyses”).
Session: Why Biobanking?
Biobanks play a crucial role in biomedicine as they maintain a wide array of biospecimens, including blood, saliva, plasma, and purified DNA, linked to phenotypic data and other trait information. Biobanksare changing the face of medical research by making available a wealth of material needed for broad research, to investigate cancerous tissues, allowing access tohealthy controls, and more. This session covers the importance of biobanks for personalized medicine, but also touches uponsome of the primary concerns associated with the management of a biobank. They include meeting standards for sample and data quality and integrity, linking biospecimens with electronic medical records in an integrated healthcare delivery system, and the protection of the individual’s rights and privacy.